Client(s) 拜玛林制药公司
美国众达律师事务所正在为拜玛林制药公司（BioMarin Pharmaceutical Inc.，纳斯达克股票代码：BMRN，以下简称“拜玛林制药”）开展以48亿美元收购爱美医疗公司（Amicus Therapeutics，纳斯达克股票代码：FOLD，以下简称“爱美医疗”）的交易提供相应法律建议。
此次收购将为拜玛林制药现有的针对溶酶体贮积病的药物组合增添两款新疗法，即，首款口服型法布里病治疗药物Galafold®（米加司他）和治疗庞贝病的双组分疗法Pombiliti®（西帕葡萄糖苷酶）+ Opfolda®（米格鲁司特）组合，进一步充实拜玛林制药的商业产品组合。
此次交易预计将在2026年第二季度完成交割，交易交割前还需获得相应的监管批准以及爱美医疗的股东批准，以及满足其他惯常交割条件。
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice
